ClinicalTrials.gg
RecruitingNCT05646381Updated Jun 23, 2026

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

A Phase 2 interventional study of Pelacarsen (TQJ230) 80mg and Matching placebo in Aortic Stenosis, sponsored by Novartis Pharmaceuticals. Recruiting at 140 sites in 15 countries. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
502
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 189 studies in Aortic Valve Stenosis with a site in United States — 44 open to participants now, 68 under way, 3 of them phase 3. Aortic Valve Stenosis · United States.

Planned enrollment
36th of 125
502 · median 172
Started
2024
with 12 others
Phase 2
5 of 189
1 open now
Primary completion
2030-03
later than 60 of 67 live
Registered
150th of 189
by date

Among the 189 studies in Aortic Valve Stenosis with a site in United States, this one is the 36th largest by planned enrollment of the 125 interventional ones that give a count, is one of 13 that started in 2024, is one of 5 in phase 2, reaches primary completion later than 60 of the 67 other live ones, and was the 150th registered.

Aortic Valve Stenosis

1,026 studies on the registry are indexed under Aortic Valve Stenosis; 294 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

44 of the 189 studies in Aortic Valve Stenosis with a site in United States are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 25 take children under 18; 14 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Aortic Valve Stenosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis.

03

Conditions studied

  • Aortic Stenosis

Keywords

  • Cardiovascular
  • Lipoprotein(a)
  • Lp(a)
  • Hyperlipoproteinemia(a)
  • Calcific aortic valve stenosis
  • TQJ230
  • Pelacarsen
  • Aortic valve stenosis
  • Aortic stenosis
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female ≥50 to \<80 years of age at Screening Part II
  • Lp(a) ≥175 nmol/L at the screening visit, measured at the Central laboratory
  • Mild or moderate calcific aortic valve stenosis
  • At the randomization visit, participant must be optimally treated for existing CV risk factors

Exclusion criteria

Exclusion Criteria:

  • Severe calcific aortic valve stenosis
  • Uncontrolled hypertension
  • History of of any organ system
  • History of hemorrhagic stroke or other major bleeding
  • count ≤ LLN
  • Active liver disease or hepatic dysfunction
  • Significant kidney disease
  • Pregnant or nursing women

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
502 participants (estimated)

Study arms

  • Experimental
    Pelacarsen (TQJ230) 80mg

    Pelacarsen (TQJ230) 80 mg prefilled syringe injected monthly, administered subcutaneously

    Drug: Pelacarsen (TQJ230) 80mg

  • Placebo comparator
    Matching placebo

    Placebo to match pelacarsen (TQJ230) prefilled syringe injected monthly, administered subcutaneously

    Drug: Matching placebo

Interventions

  • Pelacarsen (TQJ230) 80mg

    Also known as: TQJ230

  • DrugMatching placebo

    Matching placebo

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Change in peak aortic jet velocity

    To demonstrate the superiority of pelacarsen (TQJ230) vs. placebo in slowing the progression of calcific aortic valve stenosis by evaluating the change from baseline to month 36 in peak aortic jet velocity by echocardiography

    Time frame: 36 months

  2. Change in aortic valve calcium score

    To demonstrate the superiority of pelacarsen (TQJ230) vs. placebo in slowing the progression of calcific aortic valve stenosis by evaluating the change from baseline to month 36 in aortic valve calcium score by computed tomography

    Time frame: 36 months

Secondary outcomes

  1. Change in Lp(a) levels

    To assess the effect of pelacarsen (TQJ230) vs. placebo on the reduction of Lp(a) levels from baseline to month 12

    Time frame: 12 months

  2. Change in fibrocalcific thickening of the aortic valve

    To assess the effect of pelacarsen (TQJ230) vs. placebo in slowing the progression of CAVS by evaluating the change from baseline to month 36 in fibrocalcific thickening of the aortic valve by contrast CT

    Time frame: 36 months

  3. Time from randomization to first occurrence of composite clinical endpoint event

    To assess the effect of pelacarsen (TQJ230) vs. placebo in reducing the risk of composite clinical endpoint defined as reaching either: 1. Unplanned CAVS related hospital admission 2. Aortic valve intervention 3. Death related to calcific aortic valve stenosis

    Time frame: Up to 36 months

07

Study locations

130 of 140 sites recruiting
  • Heart Center Research Llc
    Huntsville, Alabama 35801, United States
    Recruiting
  • Cardiovascular Res Found
    Beverly Hills, California 90210, United States
    Recruiting
    • Juan Ramos · Contactjuan.ramos@cvmg.com · +1 310 278 3400
    • Ronald P Karlsberg · Principal investigator
  • National Heart Institute
    Beverly Hills, California 90211, United States
    Recruiting
  • Flourish Clinical Resrch Covin
    Covina, California 91723, United States
    Recruiting
  • Valley Clinical Trials
    Northridge, California 91325, United States
    Recruiting
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
    Recruiting
    • Tamara Bazouzi · Contactbazouzit@stanford.edu · +1 650 736 7878
    • Abha Khandelwal · Principal investigator
  • University Of California San Diego
    San Diego, California 92103-8415, United States
    Recruiting
  • UC San Francisco Medical Center
    San Francisco, California 94143, United States
    Recruiting
    • Liliann Zou · Contactliliann.zou@ucsf.edu · +1 415 514 3156
    • Eveline Stock · Principal investigator
  • Excel Medical Clinical Trials LLC
    Boca Raton, Florida 33434, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Nova Clinical Research LLC
    Bradenton, Florida 34209, United States
    Recruiting
  • Flourish Res Acq LLC North Miami
    Miami, Florida 33138, United States
    Recruiting
  • Inpatient Research Clinical LLC
    Miami Lakes, Florida 33014, United States
    Recruiting
  • Advanced Research for Health Improvement LLC
    Naples, Florida 34102, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Midwest Heart and Vascular Spec
    Overland Park, Kansas 66211, United States
    Recruiting
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
    Recruiting
    • Veronique Recile · Contact+1 617 636 5897
    • Benjamin Wessler · Principal investigator
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
  • Brigham and Womens Hosp Harvard Med School
    Boston, Massachusetts 02115, United States
    Recruiting
  • Brigham and Womens Hosp Harvard Med School
    Boston, Massachusetts 02115, United States
    Recruiting
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
    Recruiting
    • Jodi Carter, BS, CCRP · Contact+1 (313) 916-3613
    • Khaled Abdul-Nour · Principal investigator
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
    Recruiting
    • Jodi Carter · Contactjcarte23@hfhs.org · +1 313 590 2407
    • Khaled Abdul-Nour · Principal investigator
  • AA Medical Research Center
    Flint, Michigan 48504, United States
    Recruiting
    • Fayyaz Shah · Contactfshah@aamrc.net · +1 810 237 1125
    • Ahmed A Arif · Principal investigator
  • William Beaumont Hospital
    Royal Oak, Michigan 48073-4192, United States
    Recruiting
  • Minneapolis Heart Institute
    Minneapolis, Minnesota 55407, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University Of Minnesota
    Minneapolis, Minnesota 55455, United States
    Recruiting
    • Michelle Pitt · Contacthenni032@umn.edu · +1 612 624 4948
    • Daniel Duprez · Principal investigator
  • Overlook Medical Center
    Summit, New Jersey 07901, United States
    Recruiting
  • Capital Cardiology Associates
    Albany, New York 12211, United States
    Recruiting
  • New York Presbyterian Hospital
    New York, New York 10021, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Icahn School of Med at Mt Sinai
    New York, New York 10029, United States
    Recruiting
  • Strong Memorial Hospital
    Rochester, New York 14642, United States
    Recruiting
  • Wake Forest University Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
    Recruiting
  • Lindner Ctr At The Christ Hosp
    Cincinnati, Ohio 45219, United States
    Recruiting
  • Ohio State University
    Columbus, Ohio 43210, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Perelman School of Medicine
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Texas Heart Institute
    Houston, Texas 77030, United States
    Recruiting
  • Orion Medical
    Houston, Texas 77034, United States
    Recruiting
  • Virginia Heart
    Falls Church, Virginia 22042, United States
    Recruiting
  • Carient Heart and Vascular
    Manassas, Virginia 20109, United States
    Recruiting
    • Hameeda Tasneem · Contacthtasneem@carient.com · +1 70 333 58 750
    • Vikram Prasanna · Principal investigator
  • Novartis Investigative Site
    Innsbruck, Tyrol 6020, Austria
    Recruiting
  • Novartis Investigative Site
    Linz, 4021, Austria
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Vienna, 1100, Austria
    Recruiting
  • Novartis Investigative Site
    Vienna, 1190, Austria
    Recruiting
  • Novartis Investigative Site
    Vienna, A 1090, Austria
    Recruiting
  • Novartis Investigative Site
    Genk, Limburg 3600, Belgium
    Recruiting
  • Novartis Investigative Site
    Yvoir, Namur 5530, Belgium
    Recruiting
  • Novartis Investigative Site
    Aalst, Oost Vlaanderen 9300, Belgium
    Recruiting
  • Novartis Investigative Site
    Kortrijk, West-Vlaanderen 8500, Belgium
    Recruiting
  • Novartis Investigative Site
    Roeselare, West-Vlaanderen 8800, Belgium
    Recruiting
  • Novartis Investigative Site
    Cambridge, Ontario N1R 6V6, Canada
    Recruiting
  • Novartis Investigative Site
    North York, Ontario M6B 3H7, Canada
    Recruiting
  • Novartis Investigative Site
    Ottawa, Ontario K1Y 4W7, Canada
    Recruiting
  • Novartis Investigative Site
    Montreal, Quebec H1T 1C8, Canada
    Recruiting
  • Novartis Investigative Site
    Montreal, Quebec H3T 1E2, Canada
    Recruiting
  • Novartis Investigative Site
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
  • Novartis Investigative Site
    Québec, Quebec G1V 4G5, Canada
    Recruiting
  • Novartis Investigative Site
    Hradec Králové, 500 02, Czechia
    Recruiting
  • Novartis Investigative Site
    Jaroměř, 551 01, Czechia
    Recruiting
  • Novartis Investigative Site
    Prague, 128 08, Czechia
    Recruiting
  • Novartis Investigative Site
    Prague, 14021, Czechia
    Recruiting
  • Novartis Investigative Site
    Prague, 150 06, Czechia
    Recruiting
  • Novartis Investigative Site
    Esbjerg, 6700, Denmark
    Recruiting
  • Novartis Investigative Site
    Hvidovre, 2650, Denmark
    Recruiting
  • Novartis Investigative Site
    Roskilde, 4000, Denmark
    Recruiting
  • Novartis Investigative Site
    Viborg, 8800, Denmark
    Recruiting
  • Novartis Investigative Site
    Paris, 75012, France
    Recruiting
  • Novartis Investigative Site
    Paris, 75013, France
    Recruiting
  • Novartis Investigative Site
    Paris, 75015, France
    Recruiting
  • Novartis Investigative Site
    Pessac, 33604, France
    Recruiting
  • Novartis Investigative Site
    Poitiers, 86021, France
    Recruiting
  • Novartis Investigative Site
    Rennes, 35033, France
    Recruiting
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60594, Germany
    Recruiting
  • Novartis Investigative Site
    Kaiserslautern, Rhineland-Palatinate 67655, Germany
    Recruiting
  • Novartis Investigative Site
    Dresden, Saxony 01099, Germany
    Recruiting
  • Novartis Investigative Site
    Leipzig, Saxony 04289, Germany
    Recruiting
  • Novartis Investigative Site
    Ahaus, 48683, Germany
    Recruiting
  • Novartis Investigative Site
    Berlin, 13353, Germany
    Recruiting
  • Novartis Investigative Site
    Bonn, 53105, Germany
    Recruiting
  • Novartis Investigative Site
    Essen, 45147, Germany
    Recruiting
  • Novartis Investigative Site
    Hamburg, 20246, Germany
    Recruiting
  • Novartis Investigative Site
    Hamburg, 22763, Germany
    Recruiting
  • Novartis Investigative Site
    Lüneburg, 21339, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Mannheim, 68165, Germany
    Recruiting
  • Novartis Investigative Site
    München, 80636, Germany
    Recruiting
  • Novartis Investigative Site
    Münster, 48149, Germany
    Recruiting
  • Novartis Investigative Site
    Oldenburg, 26133, Germany
    Recruiting
  • Novartis Investigative Site
    Beersheba, 8457108, Israel
    Recruiting
  • Novartis Investigative Site
    Haifa, 3104802, Israel
    Recruiting
  • Novartis Investigative Site
    Haifa, 3109601, Israel
    Recruiting
  • Novartis Investigative Site
    Jerusalem, 9103102, Israel
    Recruiting
  • Novartis Investigative Site
    Jerusalem, 9112001, Israel
    Recruiting
  • Novartis Investigative Site
    Nahariya, 2210001, Israel
    Recruiting
  • Novartis Investigative Site
    Petah Tikva, 4941492, Israel
    Recruiting
  • Novartis Investigative Site
    Ramat Gan, 5265601, Israel
    Recruiting
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
    Recruiting
  • Novartis Investigative Site
    Ancona, AN 60126, Italy
    Recruiting
  • Novartis Investigative Site
    Bergamo, BG 24127, Italy
    Recruiting
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Brescia, BS 25123, Italy
    Recruiting
  • Novartis Investigative Site
    Caserta, CE 81100, Italy
    Recruiting
  • Novartis Investigative Site
    Cona, FE 44124, Italy
    Recruiting

Showing the first 100 of 140 sites across 15 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Nicholls SJ, Nelson AJ, Michael LF. Oral agents for lowering lipoprotein(a). Curr Opin Lipidol. 2024 Dec 1;35(6):275-280. doi: 10.1097/MOL.0000000000000953. Epub 2024 Sep 25. PubMed 39329200 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with the applicable laws and regulations.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Mar 2030, 72 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2022
First posted
Dec 12, 2022
StartActual
Mar 7, 2024
Primary completionEst.
Mar 12, 2030
CompletionEst.
Mar 12, 2030
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05646381
Responsible party
Sponsor
First posted
Dec 12, 2022
Start date
Mar 7, 2024
Primary completion
Mar 12, 2030 (estimated)
Completion
Mar 12, 2030 (estimated)
Last update
Jun 23, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pelacarsen

Start the discussion